Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Zenas BioPharma (Nasdaq: ZBIO) announced that on April 15, 2026 the company granted an aggregate of 41,475 restricted stock units (RSUs) to newly hired employees as inducement awards under Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments on April 15, 2027, April 15, 2028, April 15, 2029 and April 15, 2030, and are subject to continued service and the 2026 Inducement Plan.
Positive
- None.
Negative
- None.
News Market Reaction – ZBIO
In the Apr 20 session, ZBIO declined 4.22%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 27 | Financing priced | Negative | -16.1% | Pricing of $200M converts and common stock offering totaling $300M gross proceeds. |
| Mar 26 | Financing proposed | Negative | -16.1% | Announcement of proposed concurrent offerings of convertible notes and common stock. |
| Mar 16 | Inducement grants | Neutral | +1.1% | Inducement equity awards of stock options and RSUs to new employees. |
| Mar 16 | Earnings & update | Neutral | -2.1% | Q4 and 2025 results with positive obexelimab Phase 3 data and new debt facility. |
| Feb 20 | Inducement grants | Neutral | +1.0% | February inducement stock options and RSUs for newly hired employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent capital raises led to sharp negative reactions, while prior inducement grants and routine updates saw modest moves, suggesting financing headlines have been more price-sensitive than HR equity awards.
Over the last few months, Zenas reported positive Phase 3 obexelimab data and 2025 results, while simultaneously strengthening its balance sheet via debt and equity raises, including $200M convertible notes and 5,000,000 shares at $20.00. These financings on March 26–31, 2026 triggered notable drawdowns. By contrast, prior inducement grants in February and March 2026 were routine HR actions with relatively muted impact, similar in nature to today’s announcement.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
inducement grant financial
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on April 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted an aggregate of 41,475 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The RSUs will vest in four (4) equal installments over a four-year period, with vesting as to twenty-five percent (
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a preclinical, potentially best-in-class, oral, IL-17AA/AF inhibitor, and ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com
